Arcadia Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Arcadia Biosciences
RKDA Stock  USD 4.47  0.18  3.87%   
Arcadia Biosciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Arcadia Biosciences' valuation are provided below:
Gross Profit
2.2 M
Profit Margin
(1.39)
Market Capitalization
6.4 M
Enterprise Value Revenue
0.6122
Revenue
5.4 M
We have found one hundred twenty available fundamental signals for Arcadia Biosciences, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Arcadia Biosciences prevailing market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. The current year's Market Cap is expected to grow to about 14.7 M. The current year's Enterprise Value is expected to grow to about 5.2 M

Arcadia Biosciences Total Revenue

6 Million

Check Arcadia Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arcadia Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 107.3 K, Interest Expense of 247.1 K or Selling General Administrative of 14.4 M, as well as many indicators such as Price To Sales Ratio of 1.52, Dividend Yield of 0.0018 or PTB Ratio of 1.36. Arcadia financial statements analysis is a perfect complement when working with Arcadia Biosciences Valuation or Volatility modules.
  
Build AI portfolio with Arcadia Stock
Check out the analysis of Arcadia Biosciences Correlation against competitors.
For information on how to trade Arcadia Stock refer to our How to Trade Arcadia Stock guide.

Arcadia Biosciences Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets24.9 M13.5 M28.6 M
Pretty Stable
Short and Long Term Debt Total147.2 K155 K8 M
Slightly volatile
Other Current Liabilities1.9 M1.7 M2.3 M
Pretty Stable
Total Current Liabilities4 M2.6 M4.7 M
Pretty Stable
Property Plant And Equipment Net169.1 K178 K1.8 M
Pretty Stable
Accounts Payable756 K703 K622.8 K
Slightly volatile
Cash4 M4.2 M10.6 M
Pretty Stable
Non Current Assets Total5.3 M4.3 M6.4 M
Very volatile
Non Currrent Assets Other2.7 M4.1 M2.3 M
Pretty Stable
Cash And Short Term Investments4 M4.2 M18.2 M
Very volatile
Net Receivables3.2 M3.1 M1.3 M
Slightly volatile
Common Stock Shares Outstanding1.4 M1.4 M375.9 K
Slightly volatile
Liabilities And Stockholders Equity24.9 M13.5 M28.6 M
Pretty Stable
Non Current Liabilities Total4.5 M4.7 M13.1 M
Slightly volatile
Inventory1.5 M904 K1.3 M
Slightly volatile
Other Current Assets1 M1 M920.3 K
Slightly volatile
Other Stockholder Equity207.9 M285 M176.1 M
Slightly volatile
Total Liabilities6.9 M7.3 M17.7 M
Slightly volatile
Property Plant And Equipment Gross2.7 M2 M2.3 M
Slightly volatile
Total Current Assets8.8 M9.2 M21.4 M
Pretty Stable
Other Liabilities8.1 M6.3 M7.1 M
Very volatile
Other Assets0.860.91.8 M
Slightly volatile
Short Term Debt147.2 K155 K3.8 M
Slightly volatile
Property Plant Equipment3.1 M6.2 M3 M
Slightly volatile
Deferred Long Term Liabilities2.1 M1.8 M2.4 M
Slightly volatile
Long Term Investments2.7 M2.9 M3 M
Very volatile
Short and Long Term Debt975.6 K1 M3.9 M
Pretty Stable
Common Stock Total Equity51 K62.1 K48.3 K
Slightly volatile
Long Term Debt Total1.8 M1.9 M11.7 M
Slightly volatile
Capital Surpluse213.9 M275.4 M202.2 M
Slightly volatile
Non Current Liabilities Other1.7 M1.8 M3.9 M
Very volatile
Common Stock59 K74.8 K51.5 K
Slightly volatile
Net Invested Capital5.9 M6.2 M12 M
Slightly volatile
Net Working Capital6.3 M6.7 M14.8 M
Pretty Stable
Capital Stock63.8 K74.8 K52.5 K
Slightly volatile
Capital Lease Obligations147.2 K155 K2.1 M
Pretty Stable

Arcadia Biosciences Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization107.3 K113 K417.8 K
Pretty Stable
Selling General Administrative14.4 M9.6 M12.6 M
Slightly volatile
Total Revenue6 M5 M5.7 M
Very volatile
Other Operating Expenses24 M12.7 M21.4 M
Slightly volatile
Research Development50.4 K53 K6 M
Slightly volatile
Cost Of Revenue3.1 M3 M2.6 M
Slightly volatile
Total Operating Expenses5.4 M5.7 M17.5 M
Pretty Stable
Interest Income742.3 K782 K1.3 M
Slightly volatile
Preferred Stock And Other Adjustments2.1 M2.3 M2.5 M
Slightly volatile
Reconciled Depreciation107.3 K113 K331.2 K
Pretty Stable

Arcadia Biosciences Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation486.4 K512 K1.3 M
Pretty Stable
Begin Period Cash Flow6.2 M6.5 M11.3 M
Slightly volatile
Depreciation107.3 K113 K406.1 K
Pretty Stable
Capital Expenditures15.2 K16 K421.5 K
Pretty Stable
End Period Cash Flow4 M4.2 M10.7 M
Pretty Stable
Sale Purchase Of Stock30.4 M28.9 M12.8 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.521.599815.8732
Slightly volatile
Dividend Yield0.00180.0020.0022
Slightly volatile
Days Sales Outstanding23322290.8553
Slightly volatile
Stock Based Compensation To Revenue0.09640.10150.3604
Very volatile
Capex To Depreciation0.130.14161.1656
Very volatile
Inventory Turnover1.933.27772.2027
Pretty Stable
Days Of Inventory On Hand106111234
Slightly volatile
Payables Turnover3.784.21484.9033
Very volatile
Sales General And Administrative To Revenue3.021.842.9598
Pretty Stable
Research And Ddevelopement To Revenue0.010.01051.535
Pretty Stable
Capex To Revenue0.0030.00320.1354
Very volatile
Cash Per Share2.963.1116252
Slightly volatile
Days Payables Outstanding13886.5997118
Very volatile
Income Quality1.021.36791.192
Slightly volatile
Intangibles To Total Assets0.00270.00290.0125
Slightly volatile
Current Ratio6.683.60595.6389
Pretty Stable
Receivables Turnover1.561.64395.4639
Pretty Stable
Capex Per Share0.01110.01173.7663
Slightly volatile
Revenue Per Share3.523.700676.4474
Slightly volatile
Interest Debt Per Share0.110.1137169
Slightly volatile
Debt To Assets0.01090.01150.3316
Slightly volatile
Operating Cycle247333319
Pretty Stable
Days Of Payables Outstanding13886.5997118
Very volatile
Ebt Per Ebit1.051.18120.9676
Pretty Stable
Quick Ratio6.343.25325.3374
Pretty Stable
Net Income Per E B T0.871.63331.0876
Pretty Stable
Cash Ratio2.171.65512.5372
Pretty Stable
Days Of Inventory Outstanding106111234
Slightly volatile
Days Of Sales Outstanding23322290.8553
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.821.00171.0117
Slightly volatile
Fixed Asset Turnover29.7628.34278.5523
Slightly volatile
Debt Ratio0.01090.01150.3316
Slightly volatile
Price Sales Ratio1.521.599815.8732
Slightly volatile
Asset Turnover0.280.37320.2872
Slightly volatile

Arcadia Biosciences Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap14.7 M8.1 M24.7 M
Slightly volatile

Arcadia Fundamental Market Drivers

Forward Price Earnings36.63
Cash And Short Term Investments4.2 M

Arcadia Upcoming Events

4th of April 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
4th of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Arcadia Biosciences Financial Statements

Arcadia Biosciences stakeholders use historical fundamental indicators, such as Arcadia Biosciences' revenue or net income, to determine how well the company is positioned to perform in the future. Although Arcadia Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Arcadia Biosciences' assets and liabilities are reflected in the revenues and expenses on Arcadia Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Arcadia Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-514.8 K-489.1 K
Total Revenue5 M6 M
Cost Of Revenue3 M3.1 M
Stock Based Compensation To Revenue 0.10  0.10 
Sales General And Administrative To Revenue 1.84  3.02 
Research And Ddevelopement To Revenue 0.01  0.01 
Revenue Per Share 3.70  3.52 
Ebit Per Revenue(0.72)(0.76)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
HLNHaleon plc
NVDANVIDIA
INTCIntel
When determining whether Arcadia Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Arcadia Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Arcadia Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Arcadia Biosciences Stock:
How To Invest In Arcadia
Details
Is Arcadia Stock a good investment?
Details
What is Arcadia Biosciences' Net Worth?
Details
Largest Food, Beverage & Tobacco Companies
View
Largest Consumer Defensive Companies
View
Check out the analysis of Arcadia Biosciences Correlation against competitors.
For information on how to trade Arcadia Stock refer to our How to Trade Arcadia Stock guide.
You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Agricultural Products & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcadia Biosciences. If investors know Arcadia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arcadia Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.285
Earnings Share
(0.57)
Revenue Per Share
3.96
Quarterly Revenue Growth
0.114
Return On Assets
(0.33)
The market value of Arcadia Biosciences is measured differently than its book value, which is the value of Arcadia that is recorded on the company's balance sheet. Investors also form their own opinion of Arcadia Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Arcadia Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arcadia Biosciences' market value can be influenced by many factors that don't directly affect Arcadia Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Please note, there is a significant difference between Arcadia Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arcadia Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arcadia Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY